INFORMATION ABOUT COMPONENTS OF EQUITY - Rizobacter Argentina (Details) - USD ($)
 12 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Jun. 30, 2018
Jun. 30, 2017
Financial position        
Current assets $ 164,693,055 $ 98,208,964 $ 85,342,852  
Non-current assets 132,868,314 144,258,333 111,295,912  
Total assets 297,561,369 242,467,297 196,638,764  
Current liabilities 130,610,709 116,458,133 118,680,626  
Non-current liabilities 106,201,178 63,914,298 44,824,482  
Total liabilities 236,811,887 180,372,431 163,505,108  
Equity attributable to controlling interest 46,179,395 47,301,863 13,713,484  
Equity attributable to non-controlling interest 14,570,087 14,793,003 19,420,172  
Total equity 60,749,482 62,094,866 33,133,656 $ 77,239,066
Total liabilities and equity 297,561,369 242,467,297 196,638,764  
Summary statements of comprehensive income or loss        
Revenues 173,092,172 160,605,296 133,542,704  
Initial recognition and changes in the fair value of biological assets 716,741 279,945    
Cost of sales (93,575,588) (86,964,881) (77,094,551)  
Gross margin 79,516,584 73,640,415 56,448,153  
Research and development expenses (4,195,270) (3,689,391) (3,950,100)  
Selling, general and administrative expenses (38,345,028) (39,243,800) (35,263,688)  
Share of profit or loss of joint ventures and associates 2,477,193 1,012,486 (2,136,801)  
Other income (307,499) 365,900 613,389  
Operating profit 39,145,980 32,085,610 15,710,953  
Profit (loss) before income tax 6,443,338 (9,372,607) (25,239,763)  
Income tax (expense) benefit (2,206,710) (6,986,284) 10,928,517  
Result for the year 4,236,628 (16,358,891) (14,311,246)  
Exchange differences on translation of foreign operations (10,108,444) 5,240,151 (29,845,780)  
Revaluation of property, plant and equipment, net of tax [1] 3,399,683 (1,441,132) 8,381,618  
Total comprehensive loss $ (5,445,488) $ (12,454,526) $ (46,144,800)  
Rizobacter Argentina        
Summarized financial information        
Proportion of ownership interests held by non-controlling interests 20.00% 20.00% 40.00%  
Financial position        
Current assets $ 148,256,827 $ 115,546,951 $ 86,461,071  
Non-current assets 49,843,457 47,418,450 48,295,110  
Total assets 198,100,284 162,965,401 134,756,181  
Current liabilities 129,838,941 100,590,919 88,270,487  
Non-current liabilities 32,935,399 34,788,705 29,598,319  
Total liabilities 162,774,340 135,379,624 117,868,806  
Equity attributable to controlling interest 35,324,227 27,584,666 16,824,251  
Equity attributable to non-controlling interest 1,717 1,111 63,124  
Total equity 35,325,944 27,585,777 16,887,375  
Total liabilities and equity 198,100,284 162,965,401 134,756,181  
Summary statements of comprehensive income or loss        
Revenues 162,404,866 156,741,933 129,798,271  
Initial recognition and changes in the fair value of biological assets 716,741      
Cost of sales (86,533,561) (85,287,771) (71,699,144)  
Gross margin 76,588,046 71,454,162 58,099,127  
Research and development expenses (2,689,468) (2,367,727) (2,902,235)  
Selling, general and administrative expenses (36,103,289) (31,316,843) (31,219,784)  
Share of profit or loss of joint ventures and associates 1,960,549 1,071,297 (1,683,949)  
Other income (380,871) 286,626 524,672  
Operating profit 39,374,967 39,127,515 22,817,831  
Financial results (30,014,131) (24,650,359) (37,989,573)  
Profit (loss) before income tax 9,360,836 14,477,156 (15,171,742)  
Income tax (expense) benefit (3,830,106) (7,729,300) 3,275,077  
Result for the year 5,530,730 6,747,856 (11,896,665)  
Exchange differences on translation of foreign operations 1,281,974 17,197 (8,266,718)  
Revaluation of property, plant and equipment, net of tax 3,921,091 (1,347,124) 14,079,875  
Total comprehensive loss $ 10,733,795 $ 5,417,929 $ (6,083,508)  
[1] The tax effect of the revaluation of property, plant and equipment was $1,133,230, $(480,378) and $4,513,179 for the years ended June 30, 2020, 2019 and 2018, respectively.